Grantee Name: Dr. Stephen Baylin and Dr. Julie Brahmer
Organization:
John Hopkins University
Country: USA
Project Name:
Epigenetic therapy to sensitize patients with advanced NSCLC to chemotherapy and immunotherapy targeting reversal of immune tolerance
Funding Year:
2015
Project period: 6 years
Epigenetic therapy to sensitize patients with advanced NSCLC to chemotherapy and immunotherapy targeting reversal of immune tolerance
The team had found in an earlier study that epigenetic therapy appears to sensitize patients to subsequent treatments including chemotherapy, and very excitingly, to immunotherapy, targeting reversal of immune tolerance.